1Young JM, Spires DA, Bedord CJ,et al. The mouse ear inflammatory response to topical arachidonic acid[J]. J Invest Dermatol,1984,82: 367-371.
2Pichat P, Angel I, Arbilla S. Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat[J]. Arzneimittelforschung,1998,48(2): 173-178.
3Carayol N, Crampette L, Mainprice B,et al. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastine[J].Allergy,2002,57: 1067-1070.
4Yamada N, Funayama K. Inhibitory effects of mizolastine on the release of mediators and antagonistic effects against mediators[J]. Jpn Pharmacol Ther,1998,26: 131-138.
5Katsumi I, Ikuhisa Y, Satoru M,et al. Inhibition of leukotriene production by mizolastine, a new antiallergic agent[J]. Jpn J Pharmacol,1994,65: 19-25.
6Baroody FM,Naclerio RM. Antiallergic effects of H1 receptor antagonists[J].Allergy,2000,55: 17-27.
7Triggiani M, Giannattasio G, Balestrieri B,et al.Differential modulation of mediator release from human basophils and mast cells by mizolastine[J]. Clin Exp Allergy,2004,34: 241-249.
8Mauri J. Mattila,Ilari Paakkari. Variations among non-sedating antihistamines: are there real differences?[J] 1999,European Journal of Clinical Pharmacology(2):85～93
9A. Patat,N. Ulliac,I. Zieleniuk,D. Stubbs,C. Dunmore,B. Sexton,A. Irving,W. Jones. Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects[J] 1995,European Journal of Clinical Pharmacology(2):143～150
